Compare Southwest Airlines Co (LUV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Summit Therapeutics Inc — how do they compare? Southwest Airlines Co trades at $44.97 (market cap $22.27B), while Summit Therapeutics Inc trades at $15.3 (market cap $12.06B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.58% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LUV | SMMT | |
|---|---|---|
Market Cap | $22.27B | $12.06B |
Sector | Industrials | Health |
52-Week High | $54.80 | $26.98 |
52-Week Low | $29.67 | $12.55 |
Enterprise Value | $25.37B | $11.39B |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $44.9, down 4.57% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while revenue growth is projected to rise to $30.1B in 2026. Recent news highlights board appointments and initiatives to attract business travelers, amid a volatile fuel cost environment.
LUV presents a cautious opportunity with a consensus price target of $53.86 implying upside, supported by improving cash flow and dividend payments. Risks include fuel price volatility, execution on new business offerings, and competitive pressures, requiring careful monitoring of earnings consistency and cost management.
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
